
Leukemia
From acute leukemias to CLL and CML, molecular findings can help characterize disease and inform care.
Explore testing options ↗Explore genomic testing for solid tumors and hematologic neoplasms—from common cancers to complex and rare diseases.
Cancer biology varies from person to person. Molecular profiling can provide information that helps the care team characterize disease, assess prognosis and consider treatment options in the right clinical context.
Testing is selected by a healthcare professional based on diagnosis, clinical question and available specimen. A molecular test does not detect every cancer or guarantee a treatment match.
Use this guide to explore examples of relevant biomarkers and GTC test families. The applicable markers and testing approach depend on diagnosis, subtype, stage, specimen and clinical question.
| Cancer type / examples | Biomarkers to consider | GTC test families |
|---|---|---|
| LungNon-small cell and small cell lung cancers | EGFR · ALK · ROS1 · BRAF · KRAS · MET exon 14 skipping · RET · NTRK · ERBB2 / HER2 · PD-L1 | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| BreastDuctal, lobular and triple-negative breast cancers | ER / PR · HER2 · ESR1 · PIK3CA · AKT1 · PTEN · BRCA1/2 · PD-L1 | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| ColorectalColon and rectal adenocarcinoma | KRAS / NRAS · BRAF · MSI / MMR · HER2 · NTRK fusions | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Gastric & esophagealGastric, gastroesophageal junction and esophageal cancers | HER2 · PD-L1 · MSI / MMR · CLDN18.2 | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Pancreatic & biliaryPancreatic adenocarcinoma, cholangiocarcinoma and gallbladder cancer | KRAS · BRCA1/2 · PALB2 · MSI / MMR · NTRK · FGFR2 fusions / IDH1 in relevant biliary tumors | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Ovarian & endometrialOvarian, fallopian tube, primary peritoneal and endometrial cancers | BRCA1/2 · HRD · MSI / MMR · HER2 · FOLR1 / FRα | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| ProstateProstate adenocarcinoma and other prostate tumors | BRCA1/2 and other HRR genes · MSI / MMR · selected RNA alterations | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Bladder & urothelialBladder and other urothelial carcinomas | FGFR2/3 alterations · PD-L1 · HER2 · MSI / MMR | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Melanoma & skinCutaneous melanoma and other skin cancers | BRAF · KIT · NRAS · tumor mutation burden | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Brain & central nervous systemPrimary brain tumors and CNS involvement by cancer | IDH1/2 · selected fusions and alterations · MGMT promoter methylation when clinically appropriate | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Sarcoma & GISTSoft tissue and bone sarcomas; gastrointestinal stromal tumors | KIT · PDGFRA · NTRK and other disease-associated fusions | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
| Other & rare tumorsThyroid, head and neck, neuroendocrine, kidney and unknown primary | Tumor-specific mutations and fusions · MSI / MMR · TMB when appropriate | Solid Tumor Profile Plus Liquid Trace® Solid Tumor |
Marker examples are not a complete guideline list or a promise that every marker is reported by every profile. ER, PR, HER2, PD-L1, FOLR1 and CLDN18.2 can require IHC or other methods; MMR may be assessed by IHC, and MGMT methylation requires a separate assay. Confirm GTC assay scope, companion diagnostic status, availability and specimen requirements.
| Disease | Biomarkers to consider | GTC test families |
|---|---|---|
| Acute myeloid leukemia (AML) | NPM1 · FLT3 · IDH1/2 · TP53 · KMT2A and other fusion partners | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| Acute lymphoblastic leukemia (ALL) | BCR::ABL1 · KMT2A rearrangements · other recurrent fusion transcripts | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| Chronic lymphocytic leukemia (CLL) | TP53 · IGHV mutation status · additional disease-associated alterations | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| Chronic myeloid leukemia (CML) | BCR::ABL1 and kinase-domain mutations as clinically indicated | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| Lymphoma | B- and T-cell clonality · fusion transcripts · gene expression · chromosomal alterations | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| Multiple myeloma | Fusions · chromosomal changes · gene expression · clonality · mutations | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| MDS / CMML | TP53 · SF3B1 · ASXL1 · TET2 · other myeloid-associated genes | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| Myeloproliferative neoplasms | JAK2 · CALR · MPL · additional myeloid mutations | Hematology Profile Plus Hematology Profile Liquid Trace® Hematology |
| VEXAS syndromeAutoinflammatory condition; not a cancer | Somatic UBA1 variants · interpret alongside clinical findings and hematologic evaluation | Hematology Profile Hematology Profile Plus Liquid Trace® Hematology |
RNA-based fusion, expression and clonality testing is profile-dependent. BCR::ABL1 quantitative monitoring and other disease-specific tests may require a separate method; check the individual assay before ordering.
Biomarker recommendations vary by cancer type, disease stage, prior therapy and the intended treatment. Consult the current NCCN Clinical Practice Guidelines in Oncology and applicable therapy labels when selecting tests and interpreting results.
The disease tables above are an educational starting point, not a reproduction of NCCN recommendations. Review the current disease-specific guideline and version for the patient’s setting.
Access NCCN Guidelines ↗Recent FDA updates underscore the evolving role of biomarkers such as ESR1 in advanced breast cancer, KRAS G12C in colorectal cancer, and CLDN18.2 in gastric and GEJ cancer.
Explore FDA oncology approvals ↗The NCCN guideline versions and exact testing recommendations have not yet been independently confirmed for this draft. GTC clinical review is needed before publication.
From lung and breast cancer to rare tumors, GTC offers tissue and liquid biopsy profiling to support a range of clinical questions.
Non-small cell and small cell lung cancers; mesothelioma and thymic tumors.
Ductal and lobular cancers, including triple-negative disease.
Colorectal, gastric, esophageal, pancreatic, liver, bile duct and other gastrointestinal cancers.
Ovarian, fallopian tube, endometrial, cervical and related cancers.
Prostate, bladder and other urothelial cancers, and kidney cancers.
Head and neck tumors and thyroid cancers.
Melanoma, squamous and basal cell cancers, Merkel cell carcinoma and other skin tumors.
Soft tissue and bone sarcomas, including gastrointestinal stromal tumors.
Primary brain tumors and cancers involving the central nervous system.
Neuroendocrine tumors, cancer of unknown primary and other uncommon tumors.
Explore molecular testing across myeloid, lymphoid and plasma cell diseases, with DNA and RNA options tailored to the clinical question.

From acute leukemias to CLL and CML, molecular findings can help characterize disease and inform care.
Explore testing options ↗
Mutations, fusions, gene expression and clonality can provide complementary perspectives on lymphoid disease.
Explore testing options ↗
DNA and RNA profiling can contribute to characterization and risk assessment alongside the full workup.
Explore testing options ↗Illustrations are conceptual, not diagnostic images.
Acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), chronic lymphocytic (CLL) and other leukemias.
B-cell, T-cell and Hodgkin lymphomas, including cutaneous lymphomas.
Multiple myeloma and related plasma cell disorders.
Myelodysplastic neoplasms and overlapping disorders, including CMML.
Conditions including polycythemia vera, essential thrombocythemia and myelofibrosis.
VEXAS is an adult-onset autoinflammatory syndrome associated with acquired UBA1 variants. It can involve blood abnormalities and may coexist with MDS. It is not itself a cancer. GTC’s hematology profiles include UBA1 analysis to support evaluation in the appropriate clinical context.
Additional myeloid and lymphoid conditions; contact GTC for case-specific test selection.
Our portfolio brings together tissue, bone marrow and liquid biopsy options. Availability depends on the test and specimen.
DNA and RNA profiling for molecular alterations, fusions and expression.
View profile ↗DNA and RNA profiling for a broad range of hematologic neoplasms.
View profile ↗Cell-free DNA and RNA profiling for solid tumor and hematology applications.
Explore Liquid Trace ↗GTC offers profiling across a broad range of solid tumors and hematologic neoplasms. The appropriate test depends on the disease, clinical question and specimen; contact client services for guidance.
Liquid biopsy and tissue testing provide different information. The treating clinician determines which approach is appropriate, and tissue testing may still be needed.
No. Results may inform options, but not every finding has a matching therapy. The care team interprets findings alongside the full clinical picture.
Talk with your treating clinician, who can determine whether testing is appropriate and arrange an order.
Our client services team can help you explore testing and specimen options.